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Abstract
The aim of this study was to examine whether altered plasma
viscosity could contribute to the inappropriately low production
rate of erythropoietin (EPO) observed in patients suffering
from hypergammaglobulinemias associated with multiple my-
eloma or Waldenstrom's disease. We found that the EPO for-
mation in response to anemia in these patients was inversely
related to plasma viscosity. A similar inverse relationship be-
tween plasma viscosity and EPO production was seen in rats in
which EPO formation had been stimulated by exchange trans-
fusion and the plasma viscosity of which was thereby altered by
using exchange solutions of different composition to alter
plasma viscosity and thus whole blood viscosity independently
from hematocrit. Raising the gammaglobulin concentration to
- 40 mg/ml plasma in the rats almost totally blunted the rise
in serum EPO levels despite a fall of the hematocrit to 20%.
Determination of renal EPO mRNA levels by RNase protec-
tion revealed that the reductions in serum EPO levels at higher
plasma viscosities were paralleled by reductions in renal EPO
mRNA levels.
Taken together, our findings suggest that plasma viscosity
may be a significant inhibitory modulator of anemia-induced
EPO formation. The increased plasma viscosity in patients
with hypergammaglobulinemias may therefore contribute to
the inappropriate EPO production, which is a major reason for
the anemia developing in these patients. (J. Clin. Invest. 1993.
91:251-256.) Key words: viscosity * erythropoietin * parapro-
teinemias * gamma-globulins - dextrans
Introduction
Multiple myeloma and macroglobulinemia Waldenstrom are
frequently associated with anemia ( 1). The pathogenesis of
this type ofanemia has not yet been unequivocally clarified but
may involve bone marrow displacement and/or insufficient
stimulation oferythropoiesis. Recent studies have provided evi-
dence that erythropoietin (EPO)' levels in those patients are
inappropriately low and that this type of anemia can be mark-
edly improved by the application of recombinant human EPO
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1. Abbreviations used in this paper: EPO, erythropoietin; hct, hemato-
crit.
(2, 3). In the adult EPO is predominantly produced by the
kidneys, and its production rate is mainly determined by the
hemoglobin concentration and the arterial oxygen tension (4).
The reasons why patients suffering from hypergammaglobulin-
emias elaborate inappropriately low amounts oferythropoietin
are unknown. Reduced renal function will contribute but does
not provide a complete explanation. Another possibility is that
the altered blood rheology, namely, the increased plasma vis-
cosity in those patients could be involved. Since at present no
information exists about a possible influence ofblood viscosity
on EPO formation it appeared reasonable to us to examine
whether alterations of plasma viscosity can have an influence
on the production of erythropoietin.
To this end we have examined the correlation between EPO
production and plasma viscosity or renal function in anemic
patients suffering from hypergammaglobulinemias. Moreover,
we investigated the influence of plasma viscosity on EPO for-
mation in normal rats, in which EPO formation had been stim-
ulated by exchange transfusion.
Our findings indicate that in anemic patients with hyper-
gammaglobulinemias insufficient EPO production is corre-
lated with the increase of plasma viscosity rather than with
restriction of renal function. Moreover, we observed an inhibi-
tory effect of increasing plasma viscosity on EPO formation in
anemic rats.
Methods
Patients. Patients with documented monoclonal paraproteinemia
(Waldenstrom's macroglobulinemia or multiple myeloma), without
major impairment of renal function (serum creatinine < 150 ,mol/
liter, creatinine clearance > 30 ml/min) and without evidence of
chronic inflammatory disease (no fever and leukocyte count
< 10,000/,u with essentially normal distribution) were studied. Blood
anticoagulated with K2-EDTA was used. Hematocrit was measured
with a microcentrifuge, the platelet count was determined with an elec-
tronic particle counter. Plasma was obtained by a first centrifugation at
1,500 g for 10 min, followed by gentle aspiration of plasma and a
second 10-min centrifugation of the plasma at 1,500 g. Plasma viscos-
ity was determined in a Couette-type viscometer (model LS30; Con-
traves, Zurich, Switzerland) at 37°C and shear rates of 10.2 and 87 s-'
and the arithmetic mean was calculated. Plasma samples were deep
frozen at -20'C for EPO analysis (see below).
Blood exchange experiments in rats. Male Wistar and Sprague-
Dawley rats (body weight 180-350 g) were anesthetized with 10 mg
Nembutal intraperitoneally. When required small doses of the anes-
thetic were given repeatedly during the experiment. The anesthetized
animals were placed on a heating table. A rectal temperature probe
connected to a thermostat held the core temperature of the animal at
37.0±0.5'C by regulating the heating of the table. An arterial catheter
(either femoral or carotid) and a venous catheter (either femoral or
jugular) were inserted avoiding as far as possible any blood loss. Blood
pressure was monitored by a Statham transducer connected to the arte-
rial catheter. Blood exchange was carried out with one offour different
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solutions: (a) rat plasma prepared from donor rats; (b) Ringer's solu-
tion (130 mmol/liter Na, 4 mmol/liter K, 1.5 mmol/liter Ca, 109
mmol/liter Cl, 28 mmol/liter lactate, l0 g/liter glucose); (c) Ringer's
solution supplemented with graded doses ofrat or bovine gammaglobu-
lin (G 2885 and G 7516; Sigma Chemical Co., St. Louis, MO); or (d)
Ringer's solution containing 260 g/liter dextran 40 (mol wt - 40,000;
Pharmacia AB, Uppsala, Sweden).
The plasma exchange was started by gently aspirating 2 ml ofblood
into a syringe flushed with sodium heparin ( 10 U/ml), which was used
for the determinations of blood gases, plasma viscosity, hematocrit,
and EPO. After immediate replacement of this volume with exchange
solution, blood exchange was continued over the next 10-20 min by
simultaneous blood withdrawal on the arterial side and infusion of the
exchange solution on the venous side. After the completion of the ex-
change (time: zero) an infusion of the same solution as used for the
exchange was started with a flow rate of 0.6 ml/h to replace usual fluid
loss by perspiration and diuresis. 4 h after the completion of the ex-
change (time: 4 h) 2 ml of heparinized blood was again aspirated for
the measurement of hematocrit, plasma viscosity, EPO, and arterial
blood gas analysis.
At the end of the experiment the animals were killed by cervical
dislocation or an overdose of nembutal. The kidneys were removed
and weighed. One kidney was snap frozen in liquid nitrogen and kept at
-70°C for EPO mRNA analysis. The other kidney was cut into thin
slices, fixed in Bouin's solution, and later embedded in methacrylate.
Semi-thin sections were prepared and examined by a pathologist who
was unaware of the experimental procedures.
The hematocrit level was determined with a microcentrifuge.
Plasma was obtained by centrifuging the blood for 10 min at 1,500 g.
Plasma viscosity was measured as described above. Aliquots of the
plasma were deep frozen for the determination of EPO.
Determination of serum EPO. Serum EPO concentrations were
measured by radioimmunoassay as described (5). For human samples
human recombinant EPO was used as standard, for rat samples a rat
EPO standard was used for the standard curve.
Determination ofEPO mRNA. Kidneys from rats subjected to dif-
ferent treatments were homogenized in guanidine thiocyanate (4 mol/
liter) containing sarcosyl (0.5%), EDTA ( 10 mmol/liter), sodium ci-
trate (25 mmol/liter), and mercaptoethanol (700 mmol/liter). Total
RNA was purified by centrifugation for 20 h at 33,000 rpm on a cesium
chloride gradient (5.7 mol/liter CsCl and 100 mmol/ liter EDTA) and
EPO mRNA was measured by RNAse protection as described (6),
using a 32P-labeled EPO probe, which was a PstI/SacI fragment of the
rat EPO gene, containing 132 bp of exon V and approximately 300 bp
ofthe adjoining intron. In brief, 100 ,ug oftotal RNA was hybridized to
0.7 x 106 cpm ofradiolabeled probe in 80% formamide/40 mmol/liter
piperazine-N,N'-bis(2-ethane sulfonic acid), pH 6.4/400 mmol/liter
NaCl/liter mmol/liter EDTA at 60°C overnight, and RNase digestion
was carried out at 20°C for 30 min. Protected fragments were separated
by electrophoresis on a denaturing 10% polyacrylamide gel. Autoradi-
ography of the dried gel was performed at -70°C.
Statistics. Student's unpaired t test was used for comparison of
groups and analysis of variance to test the significance of linear and
exponential regressions. P < 0.05 was considered significant.
Results
16 patients with monoclonal paraproteinemia were studied,
some of them repeatedly during ambulatory care. They are
summarized in Table I. All the patients were anemic (hemato-
crit 17-38%) but most ofthem had normal platelet counts. The
EPO levels ranged from 15 to 246 mU/ml. The three patients
with platelet counts < 100 x 109/liter (patients 7, 8, and 15)
were those with the highest EPO levels. This suggests a general
depression of the bone marrow function by other factors with
an ensuing strong stimulation of EPO secretion. Indeed, in
patient 7 a very severe bone marrow infiltration of 70-100%
was found, in the two others a marked infiltration of 60-80%
was combined with vitamin B12-deficiency (Vitamin B12: 19
and 131 pg/ml, respectively, normal values 150-630 pg/ml).
At first sight plasma EPO levels appeared to be relatively
low when compared with the degree ofanemia and it was there-
fore of interest to see whether the inappropriately low EPO
production correlated with other clinical parameters, in particu-
lar plasma viscosity and serum creatinine concentrations. EPO
production and plasma EPO levels, however, are normally
strongly dependent on the hematocrit and the hematocrit var-
ied in a wide range among the patients under study. To allow a
correlation between the reduction of EPO production and
other clinical parameters it was necessary therefore to standard-
ize EPO production in relation to the degree ofanemia in those
patients. Since a number of studies have shown that a negative
semilogarithmic correlation exists between plasma EPO con-
centrations and the hematocrit value in nonrenal anemias
(8-10) we considered the value (log EPOpatient - log EPOnor.
ma)/(patient - hctnomal) as a standardized parameter which
we termed "EPO response." Normal EPO concentration of
healthy adults (mean hematocrit 45%) average 17 mU/ml
when measured with the radioimmunoassay used for this study
( 10). For nonrenal anemias average values for the EPO re-
sponse are in the range of6 to 10 (8-10). The EPO response for
the individual patients in this study was set into relation with
the plasma viscosity or with creatinine clearance as an indirect
indicator for renal function. In patients with more than one
measurement (patients 1-4 and 9) mean values were used. It
appeared that the EPO response was correlated with both
plasma viscosity and creatinine clearance values (Fig. 1). The
best fit between plasma viscosity and EPO-response was ob-
tained with an exponential inverse correlation: EPO response
= 4.4 X plasma viscosity(cp)-'1'3(r = -0.54; P < 0.01). The
best fit between EPO response and creatinine clearance was a
linear correlation: EPO response = -0.37 + 0.05 X creatinine
clearance (r = 0.62, P < 0.02).
The question arose as to whether there was a causal link
between EPO response and plasma viscosity. To analyze this
we have performed a series of experiments with anesthetized
rats. In these animals EPO production was stimulated by an
acute reduction of the hemoglobin concentration to half nor-
mal values induced by volume exchange transfusion (Table
II). Volume exchange was performed with solutions of differ-
ent viscosities such as Ringer's solution, rat donor plasma, or
Ringer's solution supplemented with graded doses of bovine
gammaglobulin. 4 h after conclusion of the volume exchange
plasma EPO levels were measured. As shown in Fig. 2 the in-
crease of plasma EPO levels reflecting EPO release into the
circulation was dependent on the solution used for volume
exchange. Highest EPO levels were measured with Ringer's
solution followed by plasma and Ringer's solution supple-
mented with gammaglobulin. A sham exchange experiment
(replacement with whole blood) did not elevate the EPO level
markedly (44 mU/ml).
As with the patients we have calculated the EPO re-
sponse (log EPO4 h after exch - log EPOb,fore exch) / ( hct4 h after exch
- hctbefore exch) for the individual rats and have correlated this
parameter with the plasma viscosity. As shown in Fig. 3 the
EPO response of the rats was inversely correlated with the
plasma viscosity in a very similar fashion as with the patients
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Table I. Patients with Waldenstrom's Disease and Multiple Myeloma
Pat Serum Creatinine Platelet Plasma
No. Sex Age Diagnosis creatinine clearance count viscosity* Hematocrit EPO
,umol/liter ml/min X109/liter cp % mU/liter
1 f 74 Waldenstrom (IgM Kappa) 75 45t 246 2.4 34.5 18
1.6 32.5 17
2 f 79 Myeloma (IgG Lambda) 109 35t 181 4.0 20.5 21
2.3 22.5 84
3 m 76 Waldenstrom (IgM Kappa) 133 50t 128 10.4 22.5 17
7.4 23.5 17
7.2 24.0 16
6.0 16.5 40
7.8 19.5 17
4 m 54 Waldenstrom (IgM Kappa) 106 66t 147 2.8 33.5 21
9.8 36.5 15
8.2 35.5 18
9.2 37.0 21
6.8 37.0 20
S f 58 Myeloma (IgA Lambda) 87 60$ 1.9 31.5 23
6 m 65 Waldenstrom (IgM Kappa) 89 72t 470 3.9 38.0 30
7 m 41 Waldenstrom (IgM Kappa) 91 110 16 1.5 24.5 208
8 f 63 Myeloma (IgG Kappa) 66 103 89 1.4 26.5 246
9 f 77 Waldenstrom (IgM Kappa) 107 41t 2.4 36.0 23
1.4 30.5 18
10 m 83 Waldenstrom (IgM Kappa) 98 69 263 2.8 25.5 36
11 m 71 Myeloma (IgG Kappa) 117 52t 110 1.5 24.0 145
12 f 68 Waldenstrom (IgM Kappa) 80 67t 174 1.9 29.0 46
13 f 80 Myeloma (IgG Kappa) 87 36t 128 1.4 31.0 41
14 f 78 Waldenstrom (IgM Kappa) 125 32 421 1.4 31.0 51
15 m 64 Waldenstrom (IgM Lambda) 90 71 35 2.2 17.0 180
16 f 74 Myeloma (Light chains) 67 97 430 1.7 25.0 99
* Normal range: 1.1- 1.4 cp. * Calculated according to Cockcroft and Gault (7).
lIog EPO
A hct
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Figure 1. (Left panel) Relationship between plasma viscosity and
EPO response in patients suffering from multiple myelomas and
Waldenstrom's disease. EPO response is defined as (log EPOpatient
- log EPO,,.,,,a,)/(hctjati - hctn.0,,m). The dashed line indicates the
regression line. The symbol with a cross represents a value for
nonrenal anemias as estimated from reference 10. (Right panel) Re-
lationship between creatinine clearance and EPO response in patients
suffering from multiple myelomas and Waldenstrom's disease. The
dashed line indicates the regression line.
suffering from hypergammaglobulinemias. The reason for us-
ing bovine gammaglobulin for the exchange experiments re-
sulted from the relatively poor availability of rat gammaglobu-
lin. To test for the possibility that bovine gammaglobulin
might have had nonspecific effects on EPO production in the
rats, three animals were exchanged with Ringer's solution sup-
plemented with 60 mg/ml rat gammaglobulin. In these ani-
mals hematocrit fell from 42.5±1.8% before to 22.0±1.8% 4 h
after exchange. Serum EPO levels were 21±4 and 55±3 mU/
ml (mean±SD) before and 4 h after exchange, respectively.
These values are very similar to those obtained with bovine
gammaglobulin, suggesting that a possible incompatibility was
not the reason for the dose-dependent attenuation ofEPO for-
mation by bovine gammaglobulin in the rats. Also other param-
eters that might interfere with renal EPO formation such as
changes of the arterial oxygen (Table II) or carbon dioxide
tensions or changes of hemodynamics were not different
among the different groups.
Since the plasma viscosity is causally linked with plasma
concentration of gammaglobulins, it could not be distin-
guished whether the attenuation of the EPO response was de-
pendent on the increase of viscosity or due to another effect
induced by an increased level of gammaglobulins. We there-
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Table II. Exchange Transfusion Experiments in Rats
Hct (%) Systolic blood pressure Arterial P02
Before Before Before
Exchange with exchange 4 h after exchange 4 h after exchange 4 h after Body weight
mmHg mmHg g
Ringer's 39.4±4.2 23.2±3.1 170.1±7.3 100.7±20.3 90.7±10.1 109.7±6.3 202.0±4.8
Plasma 35.3±14.8 21.5±4.1 174.0±18.2 116.3±17.0 86.7±4.7 112.2±9.4 217.6±23.3
Ringer's
+ 30 g/liter
gammaglobulin 41.6±4.9 20.7±2.0 160.8±22.0 109.2±11.6 80.8±7.3 96.2±9.8 223.8±15.1
Ringer's
+ 60 g/liter
gammaglobulin 41.2±1.9 19.8±2.1 144.2±13.5 96.0±7.4 77.9±7.9 111.5±7.1 189.4±26.5
fore attempted to increase plasma viscosity without increasing
the plasma concentration of gammaglobulin. To this end a
volume exchange transfusion with Ringer's solution supple-
mented with 260 g/liter dextran 40 was performed. Exchange
transfusion with this solution led to a similar drop in hemato-
crit as with Ringer's solution alone; the plasma viscosity, how-
ever, increased from 1.13±0.07 cp before to 1.75±0.13 cp after
exchange. The rise ofplasma EPO levels induced by the reduc-
tion ofthe hemoglobin concentration was markedly attenuated
in the presence of dextran (Fig. 4).
Histological examinations of the kidneys by light micros-
copy did not reveal obvious differences among the four groups.
(Two experiments with Ringer's solution, two with plasma ex-
change, three with gammaglobulin [60 mg/ml] and five exper-
iments with dextran). Glomeruli and interstitium were normal
in all specimens. Slight tubular necrosis or epithelial swelling
was seen in one of five and slight vacuolization of tubular epi-
thelia in four of five dextran-treated rats. Kidneys of rats ex-
changed with gammaglobulin occasionally showed tubular
casts in the medullary region.
The synthesis of EPO by the kidney was assessed by mea-
suring EPO mRNA concentrations in the kidneys 4 h after
conclusion of the blood volume exchange. As shown in Fig. 5
renal EPO mRNA levels were diminished if volume exchange
was performed with solutions which increased plasma viscos-
ity. Moreover, it was apparent that the diminuation of renal
EPO mRNA levels went in parallel with the attenuation of
plasma EPO concentrations.
Discussion
Although it is well established that altered blood oxygen avail-
ability is the principal stimulus controlling EPO production, in
,&Ilog EPO
A hct
6.0
5.01
Figure 2. Plasma EPO
concentrations in rats
before and 4 h after ex-
change transfusion,
which was performed
with Ringer's solution,
donor plasma, and
Ringer's solution sup-
plemented with bovine
gammaglobulin. EPO
values in animals ex-
changed with plasma or
supplemented Ringer's
solutions were signifi-
cantly lower than those
in animals exchanged
with pure Ringer's solu-
tion.
4.01
3.0I
2.0
1.0 1.1 1.2 1.3 1.4
plasma viscosity (cp)
Figure 3. Relationship between EPO response and plasma viscosity in
rats 4 h after exchange transfusion.
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Figure 4. Plasma EPO concentration in rats before and 4 h after ex-
change transfusion with Ringer's solution or Ringer's solution sup-
plemented with dextran 40 (260 g/liter). Dextran supplementation
caused a significant reduction in EPO values.
a number of situations EPO production is less than that ex-
pected for the reduction in hematocrit. This study aimed to
examine ifchanges ofplasma viscosity could have an influence
on EPO production and could thus contribute to the inappro-
priate EPO production observed in patients with increased
plasma viscosity (2, 3) due to monoclonal gammopathies such
as multiple myeloma or Waldenstrom's disease or polyclonal
gammopathies of severe degree occasionally seen, e.g., in rheu-
matoid arthritis (1 1, 12). In agreement with previous studies
we found that serum EPO levels are in fact relatively low in
patients with multiple myeloma or Waldenstrom's disease
when set into proportion to the degree ofanemia. This circum-
stance becomes more obvious if the EPO response, defined as
the rise of serum EPO related to the degree of anemia, is com-
pared with that ofpatients suffering from hyporegenerative ane-
mias. Our findings show an inverse correlation between EPO
response and plasma viscosity. A striking feature of this corre-
lation is that comparably small changes of plasma viscosity
correlate with marked changes of the EPO response (Fig. 1).
An impaired EPO response is characteristic for the anemia
associated with chronic renal insufficiency. Since hypergam-
maglobulinemias may induce a restriction of renal function, it
appeared reasonable to us to consider an impairment of renal
function as a possible pathophysiological mechanism for the
inappropriate EPO formation in hypergammaglobulinemic pa-
tients. The EPO response correlated with creatinine clearance,
which is surprising because it has been shown that erythropoie-
Io
I)extran Ringer $ -AIob. Plasma
1 1t ~ ~IfI I -'I ----
1 2 3 4 5 6 7 8 9 1011 12 13 14
Figure 5. RNase protection assays of renal EPO mRNA in rats ex-
changed with Ringer's solution (lanes 6-8), rat plasma (lanes 12-14),
Ringer's supplemented with 60 mg/ml gammaglobulin (lanes 9-11),
or Ringer's supplemented with dextran 40 (260 g/liter) (lanes 3-5).
Lane 1: size marker generated by HpaII digest of pBR 322 DNA; lane
2: external rat EPO mRNA standard consisting of 5 jig total RNA
from kidneys of severely anemic rats (hematocrit < 10%).
sis is unaffected at creatinine clearance values above 30-40
ml/min and renal anemia is not found above this threshold
value ( 13, 14). For this reason it is unlikely that a restriction of
renal function is the primary and only cause for the impaired
EPO formation. It was of interest therefore to see whether a rise
of plasma gammaglobulins and a related rise ofplasma viscos-
ity per se is capable to attenuate the EPO response in otherwise
normal organisms. To this end we have investigated whether
an association exists between the gammaglobulin concentra-
tion or the plasma viscosity and the EPO response to anemia in
normal rats. It turned out that the rise in plasma EPO levels in
response to the same degree of anemia was inversely related to
the gammaglobulin concentration. Since gammaglobulins are
major determinants ofplasma viscosity, the EPO response was,
not surprisingly, also inversely correlated with plasma viscosity
(Fig. 3). Interestingly, the correlation between plasma viscosity
and EPO response was rather similar for hypergammaglobulin-
emic patients and the normal rats, suggesting that the impaired
EPO response in patients may in fact be due to effects related to
the increase of gammaglobulins.
To distinguish whether the attenuation of the EPO re-
sponse in the hypergammaglobulinemic rats was linked to the
alteration of plasma viscosity or to other effects related to hy-
pergammaglobulinemia, in additional experiments plasma vis-
cosity was increased by dextran. Again this maneuver led to a
marked attenuation ofthe EPO response (Fig. 4) and we there-
fore suggest that the plasma viscosity could be a factor in deter-
mining EPO production, and could therefore account for the
impaired EPO response in hypergammaglobulinemic patients.
Nonetheless it was obvious that raising plasma viscosity by
dextran was less effective on EPO levels than a rise in plasma
viscosity induced by infusion of gammaglobulins and we can-
not explain this observation yet.
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Since an increase of plasma viscosity may impair capillary
circulation and may thus impede the release of EPO from the
renocortical interstitium into the blood flow, we examined
whether viscosity related effects on plasma EPO levels were due
to an inhibition of EPO synthesis or due to an inhibition of
EPO release. EPO production rate is primarily determined by
the EPO mRNA levels within the EPO producing cells. We
found that the impaired EPO response in the rats went in paral-
lel with decreased levels ofEPO mRNA in the kidneys, suggest-
ing that it was the synthesis of EPO rather than the release of
EPO that was attenuated by the increase of plasma viscosity
(Fig. 5).
The present study cannot determine the mechanisms by
which plasma viscosity exerts influence on the stimulation of
EPO production by anemia. Since renal capillary endothelial
cells are considered as likely candidates for producing EPO
(15, 16), one could speculate that plasma viscosity exerts an
influence on endothelial cells by changing the shear stress on
the endothelial surface. It has been found for instance that the
release of histamin ( 17), renin ( 18), endothelin ( 19), prosta-
cyclin (20, 21 ), and endothelium-derived relaxing factor (22)
are shear stress dependent, indicating that this parameter is
capable to markedly modulate endothelial function. It is likely
that mechanoreception, the most widely distributed sensory
modality, is the mechanism involved (23).
The present data have clinical implications, since it has
become common practice to administer recombinant EPO to
patients with blunted EPO response. Clinicians should be
aware that low EPO levels may represent a physiological re-
sponse ofthe organism to impending hyperviscosity and that it
may be dangerous to overcome this negative feedback control
by exogenous EPO. In this context it is noteworthy that EPO
levels are low in sickle cell anemia (24), a classical condition
with increased whole blood viscosity.
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